What Gencurix does

Gencurix is a South Korea-based molecular diagnostics company, founded in 2011 and headquartered in Seoul, that develops digital PCR-based companion diagnostic tests for precision oncology. Its product portfolio centers on the Droplex PIK3CA Test for breast cancer and four cancer gene mutation tests targeting POLE (endometrial cancer), KRAS (colorectal cancer), BRAF (thyroid cancer), and cMET (non-small cell lung cancer). The company employs 51-100 people and has secured approximately $55.8M in cumulative funding across rounds in 2018 and 2021.

The company's underlying technology is a digital PCR platform combined with proprietary biomarker discovery capabilities, designed to deliver high-sensitivity mutation detection for targeted therapy selection and minimal residual disease monitoring. Gencurix monetizes through one-time license sales of its IVD products, monetizing regulatory clearances in target markets rather than building direct commercial infrastructure. Its go-to-market relies on channel partnerships: Bio-Rad Laboratories holds exclusive supply and sales rights across 32 European countries, QIAGEN provides global commercial infrastructure through the QIAcuityDx Partnering Program, Roche Diagnostics is engaged in co-commercialization discussions, and Hitachi High-Tech leads Japan market entry.

Gencurix serves oncology laboratories, healthcare providers, and government health systems requiring CE-IVDR or local regulator-grade companion diagnostics. Its primary customer segments are vertical use cases in breast, endometrial, colorectal, thyroid, and non-small cell lung cancer diagnostics. The company has CE-IVDR certification for its four multi-cancer tests and Thailand FDA approval for the Droplex PIK3CA Test, with stated expansion intent across Southeast Asia (Vietnam, Malaysia), Eastern Europe (Slovenia), and Japan.

Name

Gencurix

Legal name

Gencurix

Website

https://gencurix.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Gencurix is a Seoul-based molecular diagnostics company developing digital PCR-based companion diagnostic tests for cancer, distributed globally through partnerships with Bio-Rad, QIAGEN, Roche Diagnostics, and Hitachi High-Tech.

Ownership category

akta.pro rank

Product category

Cancer Companion Diagnostics (Molecular Diagnostics / IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)

akta.pro secondary industries

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Cancer companion diagnostics
• Digital PCR tests
• Molecular diagnostics
• In vitro diagnostics
• Precision oncology assays

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Digital PCR-based Companion Diagnostics: Revenue from digital PCR-based in vitro diagnostic products including the Droplex PIK3CA Test for breast cancer companion diagnostics. Products are sold through regulatory approvals in target markets and distributed via channel partners.
2. CE-IVDR Certified Cancer Gene Tests: Revenue from CE-IVDR certified cancer gene mutation tests (POLE, KRAS, BRAF, cMET) sold across Europe through Bio-Rad exclusive supply and sales contract covering 32 European countries.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels2 records

Core offering

Gencurix develops and sells digital PCR-based companion diagnostic (CDx) tests for precision oncology, detecting cancer-driving gene mutations to guide targeted therapy selection. Its product portfolio includes the Droplex PIK3CA Test for breast cancer and four CE-IVDR certified cancer gene mutation tests (POLE for endometrial cancer, KRAS for colorectal cancer, BRAF for thyroid cancer, and cMET for non-small cell lung cancer). Products are sold as in vitro diagnostic kits/reagents to healthcare providers and laboratories globally through channel partners and direct market entries.

Product overview

Gencurix is a cancer molecular diagnostics company offering a portfolio of digital PCR-based companion diagnostic tests for precision oncology. The company's product portfolio includes the Droplex PIK3CA Test for breast cancer and a suite of cancer gene mutation tests (POLE for endometrial cancer, KRAS for colorectal cancer, BRAF for thyroid cancer, and cMET for non-small cell lung cancer). These tests are designed to detect specific genetic mutations to guide targeted therapy selection and monitoring in cancer treatment. The products operate on digital PCR technology platforms and have received regulatory approvals including CE-IVDR certification for European markets and Thailand FDA approval for select products.

Differentiator

Problem solved

Functional benefit

Brands

• Droplex PIK3CA Test: Digital PCR-based breast cancer companion diagnostic test

Products and services

• Droplex PIK3CA Test Digital PCR-based breast cancer companion diagnostic test that detects PIK3CA mutations in patient samples to guide targeted therapy selection for breast cancer patients. Approved by Thailand FDA and used by hospital laboratories and oncology centers.
• POLE Test Digital PCR-based cancer gene mutation test for detecting POLE mutations in endometrial cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.
• KRAS Test Digital PCR-based cancer gene mutation test for detecting KRAS mutations in colorectal cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.
• BRAF Test Digital PCR-based cancer gene mutation test for detecting BRAF mutations in thyroid cancer. CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.
• cMET Test Digital PCR-based cancer gene mutation test for detecting cMET mutations in non-small cell lung cancer (NSCLC). CE-IVDR certified for diagnostic use across European markets and sold through Bio-Rad's 32-country European distribution network.

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and strategic.

• Bio-Rad LaboratoriescoreChannel Partner/ Reseller/ Distributor · 22 January 2026Exclusive supply and sales contract with Bio-Rad Laboratories covering 32 European countries. Gencurix products converted from IVDD to stricter IVDR system with Bio-Rad distribution. Partnership covers all existing product lines including cancer gene mutation tests (POLE, KRAS, BRAF, cMET).
• QIAGENcoreStrategic or Co-development Partner · 18 June 2025QIAcuity Digital PCR IVD assay development partnership for oncology assays on QIAcuityDx platform. Gencurix is inaugural partner in QIAGEN's new QIAcuityDx Partnering Program. Collaboration aims to create multiplex IVD assays for tissue and liquid biopsy applications. Gencurix responsible for regulatory approvals, leveraging QIAGEN's global commercial infrastructure.
• Roche DiagnosticsstrategicStrategic or Co-development Partner · 1 January 2025Engaged in co-commercialization discussions with Roche Diagnostics. Foundations for joint development and global commercialization cooperation in molecular diagnostics taking shape. Partnership discussions part of global expansion strategy.
• Hitachi High-TechstrategicStrategic or Co-development Partner · 28 August 2024Partnership to develop cancer molecular diagnostics business and launch testing services in Japan. Combines Hitachi High-Tech's R&D and manufacturing expertise with Gencurix's biomarker discovery technology.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Asuragen (Bio-Techne): Asuragen, a Bio-Techne company, is a direct peer developing companion diagnostics and molecular oncology assays including BRAF, KRAS, and other cancer mutation tests. Highly comparable in CDx focus and oncology gene mutation testing portfolio.
• Amoy Diagnostics: Amoy Diagnostics is an Asia-based precision oncology company specializing in companion diagnostics for EGFR, KRAS, BRAF, and other cancer gene mutations. Directly comparable in CDx product portfolio, Asian market positioning, and oncology gene mutation test focus.
• Burning Rock Biotech: Burning Rock Biotech is a China-based precision oncology diagnostics company offering NGS-based cancer gene mutation testing and companion diagnostics. Comparable as an Asian-headquartered oncology CDx company with international distribution ambitions.

Broad incumbents

• QIAGEN: QIAGEN is both a Gencurix partner and a broad incumbent in molecular diagnostics with the QIAcuity digital PCR platform. Comparable through its QIAcuityDx clinical dPCR system and oncology IVD assay development program that overlaps directly with Gencurix's product strategy.
• Bio-Rad Laboratories: Bio-Rad is Gencurix's exclusive European distributor and a major digital PCR incumbent via its QXDx ddPCR system. Comparable as both a competing dPCR platform provider and a channel partner in oncology molecular diagnostics.
• Roche Diagnostics: Roche Diagnostics is in co-commercialization discussions with Gencurix and operates broadly in molecular diagnostics including PCR-based oncology tests and companion diagnostics. Comparable as a global incumbent whose diagnostics division overlaps significantly with Gencurix's target markets.
• Exact Sciences: Exact Sciences is a precision oncology diagnostics company with Cologuard and the Oncotype DX franchise. Comparable as a precision diagnostics company commercializing cancer-related molecular tests at scale.
• NeoGenomics: NeoGenomics is a US-based oncology diagnostics company providing comprehensive cancer testing services including molecular and genetic profiling. Comparable as a commercial-stage oncology diagnostics company with multi-cancer testing menu.

Emerging players

• Guardant Health: Guardant Health is a precision oncology company specializing in liquid biopsy and blood-based cancer mutation profiling for therapy selection. Comparable in oncology CDx and gene mutation detection, though focused on liquid biopsy rather than tissue-based dPCR.
• Personalis: Personalis is a precision oncology company offering tumor profiling and companion diagnostics services via NextGen sequencing. Comparable as a precision oncology player developing CDx products, though platform technology differs from Gencurix's dPCR focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gencurix